COLL Earnings Date: Nov 5, 2026 (Estimated) — Collegium Pharmaceutical, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is COLL's next earnings date?
Collegium Pharmaceutical, Inc. (COLL) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.86 on revenue of $216.0M.
How did COLL do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Collegium Pharmaceutical, Inc. posted EPS of $1.92 versus the $1.72 estimate, a beat of 12.9%. Revenue was $199.9M against a $199.6M estimate. The stock's 1-day post-earnings move was -18.6%.
How much does COLL stock move after earnings?
COLL beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.0% (up or down) in the day after earnings.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 1.72 | 1.92 | +12.94% | $199.9M | ✅ Beat | -18.55% | -28.09% | -33.69% |
| 2026-05-07 | Q1 2026 | 1.46 | 1.76 | +20.55% | $193.5M | ✅ Beat | +7.72% | -4.49% | -8.57% |
| 2026-02-26 | Q4 2025 | 2.09 | 2.04 | -2.39% | $205.4M | ❌ Miss | -3.34% | -13.42% | -26.95% |
| 2025-11-06 | Q3 2025 | 1.79 | 2.25 | +25.70% | $209.4M | ✅ Beat | +13.42% | +32.08% | +33.64% |
| 2025-02-27 | Q4 2024 | 1.54 | 1.75 | +13.64% | $181.9M | ✅ Beat | +2.22% | +4.86% | +4.54% |
| 2024-11-07 | Q3 2024 | 1.59 | 1.61 | +1.26% | $159.3M | ✅ Beat | -7.35% | -12.79% | -11.81% |
| 2024-08-08 | Q2 2024 | 1.51 | 1.62 | +7.28% | $145.3M | ✅ Beat | +0.51% | +0.45% | +3.91% |
| 2024-02-22 | Q4 2023 | 0.66 | 1.58 | +139.39% | $149.7M | ✅ Beat | +10.79% | +11.89% | +21.06% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $135.8M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Belbuca | 42.5% | $57.7M | +9.6% | $107.4M | $51.7M | $52.6M | $58.3M |
| Xtampza ER | 33.1% | $45.0M | -14.4% | $96.0M | $47.6M | $52.6M | $50.5M |
| Nucynta ER | 11.6% | $15.7M | -21.2% | $36.8M | $19.7M | $19.9M | $22.8M |
| Nucynta IR | 10.6% | $14.4M | -45.8% | $49.4M | $27.4M | $26.5M | $32.0M |
| Symproic | 2.2% | $3.0M | -18.9% | $8.3M | $2.8M | $3.7M | $4.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.